27,912 Merck & Co., Inc. $MRK Shares Bought by Stokes Capital Advisors LLC

Stokes Capital Advisors LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 519.5% during the third quarter, HoldingsChannel.com reports. The fund owned 33,285 shares of the company’s stock after buying an additional 27,912 shares during the quarter. Stokes Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $4,837,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Mirador Capital Partners LP boosted its holdings in shares of Merck & Co., Inc. by 2.0% in the 3rd quarter. Mirador Capital Partners LP now owns 6,000 shares of the company’s stock worth $872,000 after buying an additional 118 shares during the last quarter. Capital Advisors Wealth Management LLC increased its holdings in Merck & Co., Inc. by 2.9% during the third quarter. Capital Advisors Wealth Management LLC now owns 4,756 shares of the company’s stock worth $691,000 after buying an additional 134 shares during the last quarter. Decker Wealth Management LLC bought a new stake in Merck & Co., Inc. in the third quarter worth about $379,000. Riversedge Advisors LLC raised its position in Merck & Co., Inc. by 13.8% in the third quarter. Riversedge Advisors LLC now owns 7,830 shares of the company’s stock worth $1,138,000 after acquiring an additional 950 shares during the period. Finally, Wedmont Private Capital raised its position in Merck & Co., Inc. by 39.4% in the third quarter. Wedmont Private Capital now owns 39,432 shares of the company’s stock worth $5,614,000 after acquiring an additional 11,142 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck is participating in a broad rally across biotechnology and vaccine stocks, providing sector-wide momentum for MRK shares. Novavax Soars, Moderna Surges, Merck Climbs as Biotech Rallies
• Positive Sentiment: The FDA approved Merck’s WELIREG plus LENVIMA combination for adults with advanced kidney cancer previously treated with PD-1 or PD-L1 therapies. The approval expands Merck’s oncology opportunity beyond its core Keytruda franchise. Merck also started a Phase I trial involving Cyprumed’s oral peptide-delivery platform, adding a potential pipeline catalyst. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer
• Positive Sentiment: Cantor Fitzgerald raised its Merck price target to $145 from $120, while Morgan Stanley maintained or issued a Buy view in separate coverage. These actions suggest some analysts see the recent weakness and long-term growth prospects as attractive. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Neutral Sentiment: Apella Capital increased its Merck position by 16.6% to 43,902 shares. The purchase indicates institutional confidence, although the position is too small to materially affect Merck’s fundamentals. Apella Capital Increases Stake in Merck
• Negative Sentiment: A Dutch court blocked Merck’s planned subcutaneous Keytruda product in eight European markets amid a patent dispute with Halozyme. The ruling could delay a potentially important reformulation and complicate efforts to extend Keytruda’s commercial life. HALO Wins Court Order Blocking Merck’s Keytruda SC in Europe
• Negative Sentiment: Merck is viewed as one of the pharmaceutical companies most exposed to upcoming patent losses and generic competition, raising longer-term concerns about revenue after Keytruda’s exclusivity period. Analysts have also flagged mixed growth prospects, while Morgan Stanley issued a separate pessimistic forecast. Pharma’s $500 Billion Patent Problem Will Come in Waves

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the sale, the executive vice president owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Chirfi Guindo sold 15,000 shares of the stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the sale, the executive vice president owned 46,613 shares in the company, valued at approximately $6,106,303. This represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock worth $29,977,783 in the last three months. Insiders own 0.17% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on MRK. Bank of America increased their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. The Goldman Sachs Group lifted their price target on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Argus upped their price objective on Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. TD Cowen increased their price objective on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, September 23rd. Finally, Royal Bank Of Canada lowered Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and increased their price objective for the company from $142.00 to $150.00 in a report on Thursday, August 20th. Seventeen equities research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $151.32.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $145.52 on Friday. The company has a market cap of $359.03 billion, a PE ratio of 116.42, a price-to-earnings-growth ratio of 6.41 and a beta of 0.21. Merck & Co., Inc. has a 52 week low of $82.01 and a 52 week high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The firm’s 50-day simple moving average is $143.90 and its two-hundred day simple moving average is $128.28.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the business earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.67 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were issued a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.